Galectin Therapeutics (GALT) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)

Galectin Therapeutics (GALT) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Galectin Therapeutics 185.83 Mn 171.73 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 4.38%
Dec 31, 2025 6.82%
Sep 30, 2025 -6.67%
Jun 30, 2025 -4.18%
Mar 31, 2025 -22.03%
Dec 31, 2024 -18.25%
Sep 30, 2024 -31.86%
Jun 30, 2024 -32.33%
Mar 31, 2024 -4.80%
Dec 31, 2023 -24.61%
Sep 30, 2023 -35.75%
Jun 30, 2023 -17.44%
Mar 31, 2023 -20.47%
Dec 31, 2022 -30.87%
Sep 30, 2022 -12.98%
Jun 30, 2022 -15.01%
Mar 31, 2022 -13.74%
Dec 31, 2021 -8.41%
Sep 30, 2021 -13.00%
Jun 30, 2021 -7.88%